Elbahlawan Lama, Bissler John, Morrison R Ray
Division of Critical Care Medicine, St. Jude Children's Research Hospital, Memphis, TN, United States.
Department of Pediatrics, University of Tennessee Health Science Center and Le Bonheur Children's Hospital, Memphis, TN, United States.
Front Oncol. 2021 Feb 26;11:632263. doi: 10.3389/fonc.2021.632263. eCollection 2021.
Hematopoietic stem cell transplant (HSCT) is a curative therapy for malignant and non-malignant conditions. However, complications post-HSCT contribute to significant morbidity and mortality in this population. Acute kidney injury (AKI) is common in the post-allogeneic transplant phase and contributes to morbidity in this population. Continuous renal replacement therapy (CRRT) is used often in the setting of AKI or multiorgan dysfunction in critically ill children. In addition, CRRT can be useful in many disease processes related to transplant and can potentially improve outcomes in this population. This review will focus on the use of CRRT in critically ill children in the post-HSCT setting outside the realm of acute renal failure and highlight the benefits and applications of this modality in this high-risk population.
造血干细胞移植(HSCT)是治疗恶性和非恶性疾病的一种治愈性疗法。然而,HSCT后的并发症导致该人群出现显著的发病率和死亡率。急性肾损伤(AKI)在异基因移植后阶段很常见,并导致该人群出现发病情况。连续性肾脏替代疗法(CRRT)常用于危重症儿童的AKI或多器官功能障碍情况。此外,CRRT在许多与移植相关的疾病过程中可能有用,并且有可能改善该人群的预后。本综述将聚焦于在急性肾衰竭范围之外的HSCT后环境中危重症儿童使用CRRT的情况,并强调这种治疗方式在这个高危人群中的益处和应用。